Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia; Leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results (n=40; data cut-off October 2017) assessing efficacy of ruxolitinib in chronic neutrophilic leukemia or atypical chronic myeloid leukemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 31 Aug 2018 Biomarkers information updated
- 11 May 2017 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.